Non-medical switch from the originator to biosimilar and between biosimilars of adalimumab in inflammatory bowel disease – a prospective, multicentre study

Digestive and Liver Disease（2022）

引用 7|浏览5

暂无评分

摘要

Clinical benefit was sustained following non-medical switch from originator to biosimilar, or between biosimilars in adalimumab treated IBD patients.

查看译文

关键词

Adalimumab,Biosimilar,Drug sustainability,Efficacy,Non-medical switch,Safety

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要